Literature DB >> 26932460

Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.

R Vassena1, B Heindryckx2, R Peco3, G Pennings4, A Raya5, K Sermon6, A Veiga7.   

Abstract

BACKGROUND: With the recent development of CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 genome editing technology, the possibility to genetically manipulate the human germline (gametes and embryos) has become a distinct technical possibility. Although many technical challenges still need to be overcome in order to achieve adequate efficiency and precision of the technology in human embryos, the path leading to genome editing has never been simpler, more affordable, and widespread. OBJECTIVE AND RATIONALE: In this narrative review we seek to understand the possible impact of CRISR/Cas9 technology on human reproduction from the technical and ethical point of view, and suggest a course of action for the scientific community. SEARCH
METHODS: This non-systematic review was carried out using Medline articles in English, as well as technical documents from the Human Fertilisation and Embryology Authority and reports in the media. The technical possibilities of the CRISPR/Cas9 technology with regard to human reproduction are analysed based on results obtained in model systems such as large animals and laboratory rodents. Further, the possibility of CRISPR/Cas9 use in the context of human reproduction, to modify embryos, germline cells, and pluripotent stem cells is reviewed based on the authors' expert opinion. Finally, the possible uses and consequences of CRISPR/cas9 gene editing in reproduction are analysed from the ethical point of view. OUTCOMES: We identify critical technical and ethical issues that should deter from employing CRISPR/Cas9 based technologies in human reproduction until they are clarified. WIDER IMPLICATIONS: Overcoming the numerous technical limitations currently associated with CRISPR/Cas9 mediated editing of the human germline will depend on intensive research that needs to be transparent and widely disseminated. Rather than a call to a generalized moratorium, or banning, of this type of research, efforts should be placed on establishing an open, international, collaborative and regulated research framework. Equally important, a societal discussion on the risks, benefits, and preferred applications of the new technology, including all relevant stakeholders, is urgently needed and should be promoted, and ultimately guide research priorities in this area.
© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CRISPR/Cas9; genome editing; germline modification; human embryo; oocyte; sperm; stem cells

Mesh:

Substances:

Year:  2016        PMID: 26932460     DOI: 10.1093/humupd/dmw005

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  25 in total

Review 1.  ALWAYS ICSI? A SWOT analysis.

Authors:  E Bosch; J J Espinós; F Fabregues; J Fontes; J García-Velasco; J Llácer; A Requena; M A Checa; J Bellver
Journal:  J Assist Reprod Genet       Date:  2020-06-24       Impact factor: 3.412

2.  On the confluence of reproductive and regenerative medicines.

Authors:  David F Albertini
Journal:  J Assist Reprod Genet       Date:  2018-03       Impact factor: 3.412

3.  Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE.

Authors:  Guido De Wert; Björn Heindryckx; Guido Pennings; Angus Clarke; Ursula Eichenlaub-Ritter; Carla G van El; Francesca Forzano; Mariëtte Goddijn; Heidi C Howard; Dragica Radojkovic; Emmanuelle Rial-Sebbag; Wybo Dondorp; Basil C Tarlatzis; Martina C Cornel
Journal:  Eur J Hum Genet       Date:  2018-01-12       Impact factor: 4.246

4.  Healthy children without fear: Reproductive options for patients or couples carrying inherited diseases.

Authors:  Joep Geraedts
Journal:  EMBO Rep       Date:  2017-04-10       Impact factor: 8.807

5.  Lipofection of Non-integrative CRISPR/Cas9 Ribonucleoproteins in Male Germline Stem Cells: A Simple and Effective Knockout Tool for Germline Genome Engineering.

Authors:  Mariella Obermeier; Jim Vadolas; Stefaan Verhulst; Ellen Goossens; Yoni Baert
Journal:  Front Cell Dev Biol       Date:  2022-06-14

6.  Bacterial magnetic particles improve testes-mediated transgene efficiency in mice.

Authors:  Chao Wang; Guanghong Sun; Ye Wang; Nana Kong; Yafei Chi; Leilei Yang; Qiliang Xin; Zhen Teng; Xu Wang; Yujun Wen; Ying Li; Guoliang Xia
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 7.  Spermatogonial stem cell autotransplantation and germline genomic editing: a future cure for spermatogenic failure and prevention of transmission of genomic diseases.

Authors:  Callista L Mulder; Yi Zheng; Sabrina Z Jan; Robert B Struijk; Sjoerd Repping; Geert Hamer; Ans M M van Pelt
Journal:  Hum Reprod Update       Date:  2016-05-30       Impact factor: 15.610

8.  CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo.

Authors:  Xin Xu; Jiangfeng Li; Yi Zhu; Bo Xie; Xiao Wang; Song Wang; Haiyun Xie; Huaqing Yan; Yufan Ying; Yiwei Lin; Ben Liu; Wei Wang; Xiangyi Zheng
Journal:  Oncotarget       Date:  2017-10-27

Review 9.  Therapies targeting DNA and RNA in Huntington's disease.

Authors:  Edward J Wild; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2017-09-12       Impact factor: 44.182

Review 10.  Optimization of genome editing through CRISPR-Cas9 engineering.

Authors:  Jian-Hua Zhang; Poorni Adikaram; Mritunjay Pandey; Allison Genis; William F Simonds
Journal:  Bioengineered       Date:  2016-04       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.